



Accelero Signs Service Agreement for AAV-Based Gene Therapy Development

Berlin, 21 October 2019

Accelero Bioanalytics GmbH (“Accelero”) signed an agreement with the gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”) to support the non-clinical development of an Adeno-associated virus (AAV) with its bioanalytical and regulatory expertise.

CombiGene is developing a breakthrough gene therapy with potential to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment.

Accelero will be responsible to develop and validate an appropriate quantitative PCR assay for the detection of the AAV-based drug product in a broad panel of biomaterials.

Another integral part of the agreement is the development and validation of suitable immunogenicity assays to detect an immune response against the drug product and its expressed transgene(s).

All services will be provided in full compliance to Good Laboratory Practice (GLP) regulations.

For additional information on Accelero’s services, please feel free to use our website contact form, or send us an email to [service\(at\)accelero-bioanalytics.com](mailto:service(at)accelero-bioanalytics.com). The Accelero team will be happy to assist you.

Accelero Bioanalytics GmbH
Center for Biotechnology and Environment
Volmerstrasse 9A
12489 Berlin
GERMANY

Primary Contact:
Christian Lange, Founder & Managing Director
Telephone +49 30 610 910 300

qPCR
Biodistribution
ELISA
EliSpot / FluoroSpot
Flow cytometry
Multiplex immunoassays
Multiplex miRNA assays
Cell culture
Microbiology
GLP trainings & seminars

Follow us on



Read binding-assay.com for blog and case studies.